EUVIMEDEUVIMED entdecken
Open Access

Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis

Anushka K Palipana, Emrah Gecili, Seongho Song, Simon R Johnson, Rhonda D Szczesniak, Nishant Gupta

CHEST · 2023-06 · 163 (6) · 1458-1470

DOI: 10.1016/j.chest.2022.12.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2023-06. Verfasst von Anushka K Palipana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Division of Statistics and Data Science, U…. Hauptthemen laut MEDLINE: Lung Neoplasms, Lymphangioleiomyomatosis, Lung Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung function decline varies significantly in patients with lymphangioleiomyomatosis (LAM), impeding individualized clinical decision-making. RESEARCH QUESTION: Can we aid individualized decision-making in LAM by developing a dynamic prediction model that can estimate the probability of clinically relevant FEV1 decline in patients with LAM before treatment initiation? STUDY DESIGN AND METHODS: Patients observed in the US National Heart, Lung, and Blood Institute (NHLBI) Lymphangioleiomyomatosis Registry were included. Using routinely available variables such as age at diagnosis, menopausal status, and baseline lung function (FEV1 and diffusing capacity of the lungs for carbon monoxide [Dlco]), we used novel stochastic modeling and evaluated predictive probabilities for clinically relevant drops in FEV1. We formed predictive probabilities of transplant-free survival by jointly modeling longitudinal FEV1 and lung transplantation or death events. External validation used the UK Lymphangioleiomyomatosis Natural History cohort. RESULTS: Analysis of the NHLBI Lymphangioleiomyomatosis Registry and UK Lymphangioleiomyomatosis Natural History cohorts consisted of 216 and 185 individuals, respectively. We derived a joint model that accurately estimated the risk of future lung function decline and 5-year probabilities of transplant-free survival in patients with LAM not taking sirolimus (area under the receiver operating characteristic curve [AUC], approximately 0.80). The prediction model provided estimates of forecasted FEV1, rate of FEV1 decline, and probabilities for risk of prolonged drops in FEV1 for untreated patients with LAM with a high degree of accuracy (AUC > 0.80) for the derivation cohort as well as the validation cohort. Our tool is freely accessible at: https://anushkapalipana.shinyapps.io/testapp_v2/. INTERPRETATION: Longitudinal modeling of routine clinical data can allow individualized LAM prognostication and assist in decision-making regarding the timing of treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsLymphangioleiomyomatosisLung TransplantationHumansLungDisease ProgressionForced Expiratory Volume

Stichwörter der Autor:innen

medical monitoringonline calculatorprognostic studypulmonary functionregistry data

Autor:innen und Institutionen

  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Division of Statistics and Data Science, University of Cincinnati, Cincinnati, OH.
  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Division of Statistics and Data Science, University of Cincinnati, Cincinnati, OH.
  • Translational Medical Sciences, NIHR Biomedical Research Centre and Biodiscovery Institute, University of Nottingham, Nottingham University Hospitals NHS Trust, Nottingham, England; National Centre for Lymphangioleiomyo…
  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
  • Division of Pulmonary Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH; Medical Service, Veterans Affairs Medical Center, Cincinnati, OH. Electronic address: guptans@ucmail.uc.edu.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Palipana, A. K., Gecili, E., Song, S., Johnson, S. R., Szczesniak, R. D., & Gupta, N. (2023). Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis. CHEST, 163(6), 1458-1470. https://doi.org/10.1016/j.chest.2022.12.027

Vancouver

Palipana AK, Gecili E, Song S, Johnson SR, Szczesniak RD, Gupta N. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis. CHEST. 2023;163(6):1458-1470. doi:10.1016/j.chest.2022.12.027

BibTeX
@article{Palipana2023,
  author = {Palipana, Anushka K and Gecili, Emrah and Song, Seongho and Johnson, Simon R and Szczesniak, Rhonda D and Gupta, Nishant},
  title = {Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis},
  journal = {CHEST},
  year = {2023},
  volume = {163},
  number = {6},
  pages = {1458--1470},
  doi = {10.1016/j.chest.2022.12.027}
}
Kostenlos starten →